CD8 cell fitness predicts who benefits most from antibody-based cure strategies
Antibody from Tanzanian woman suppresses almost all tested HIV variants including resistant viruses in pre-clinical study
Broadly neutralising antibodies plus immune modulator may delay HIV rebound
Broadly neutralising antibody N6LS could be part of long-acting HIV treatment
Lenacapavir plus broadly neutralising antibodies could be twice-yearly HIV treatment
Half the men in an HIV cure study stayed off treatment for nearly a year after a two-antibody shot
Novel antibody-based regimen keeps HIV at bay for six months
Top 5 stories on new drugs for HIV prevention and treatment from CROI 2023
Lenacapavir plus broadly neutralising antibodies may offer twice-yearly treatment option
